Clinical Trials
14 trialsNCT03740165 2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01226394 2026-04-06
ProphyloCHIP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT03038100 2023-02-17
IMagyn050
Hoffmann-La Roche
Phase 3 Completed
NCT01462890 2022-07-20
BOOST
AGO Study Group
Phase 3 Completed
NCT02231086 2021-09-16
COLOPEC
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 3 Completed
NCT02158988 2021-07-29
GASTRIPEC
Charite University, Berlin, Germany
Phase 3 Completed
NCT00262990 2020-12-17
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Novartis
Phase 3 Completed
NCT00216372 2020-11-05
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
Ipsen
Phase 3 Completed
NCT01846611 2019-04-01
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research & Development, LLC
Phase 3 Completed
NCT01015118 2017-12-07
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Boehringer Ingelheim
Phase 3 Completed
NCT00769405 2016-08-30
Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
UNICANCER
Phase 3 Completed
NCT00382811 2016-07-18
OVATURE
MEI Pharma, Inc.
Phase 3 Completed
NCT00191646 2011-03-04
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
Eli Lilly and Company
Phase 3 Completed
NCT00191607 2007-01-26
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
Eli Lilly and Company
Phase 3 Completed